Objective-The fibroblast growth factor (FGF)/FGF receptor system plays an important role in smooth muscle cell (SMC) activation. Long-pentraxin 3 (PTX3) is a soluble pattern recognition receptor with non-redundant functions in inflammation and innate immunity. PTX3 is produced by different cell types of the vessel wall, including SMCs. PTX3 binds FGF2 and inhibits its angiogenic activity on endothelial cells. We investigated the capacity of PTX3 to affect FGF2-dependent SMC activation in vitro and in vivo. Methods and Results-When added to human coronary artery SMCs, human PTX3 inhibits cell proliferation driven by endogenous FGF2 and the mitogenic and chemotactic activity exerted by exogenous recombinant FGF2. Accordingly, PTX3 prevents 125 I-FGF2 interaction with FGF receptors on the same cells. Also, PTX3 overexpression after recombinant adeno-associated virus-PTX3 gene transfer inhibits human coronary artery SMC proliferation and survival promoted by FGF2 in vitro. Consistently, a single local endovascular injection of recombinant adeno-associated virus-PTX3 gene inhibits intimal thickening after balloon injury in rat carotid arteries. 
xcessive growth of vascular smooth muscle cells (SMCs) is an important component in atherosclerosis and restenosis. Fibroblast growth factors (FGFs), a family of pleiotropic heparin-binding growth factors, 1 exert their activity by interacting with tyrosine-kinase receptors (FGFRs) on target cells. 2 The FGF/FGFR system plays an important role in SMC activation in vitro and in vivo after arterial injury. Indeed, FGF2 promotes survival, proliferation, and migration of SMCs [3] [4] [5] [6] that express FGFRs. 7 FGFs are expressed in injured arteries and contribute to intimal thickening. 8, 9 Accordingly, arterial injury leads to FGFR upregulation in SMCs. 8, 10 Also, most of the cell types found in the restenotic area, eg, endothelial cells, macrophages, T-cells, and SMCs themselves, synthesize FGFs, 11 the production and release of which is modulated by inflammatory mediators, 12, 13 hypoxia, 14 and cell damage. 15 Pentraxin 3 (PTX3) is the prototypic member of the long-pentraxin family. 16 PTX3 is a glycosylated protein whose C-terminal pentraxin domain shares homology with the entire sequence of the classic short-pentraxins C-reactive protein and serum amyloid P (SAP) component, whereas its NH 2 -terminal portion does not show homology with any other known protein. PTX3 is a soluble pattern recognition receptor with unique non-redundant functions in various physiopathological conditions and may serve as a mechanism of amplification of inflammation and innate immunity. 16 Unlike short-pentraxins produced by the liver in response to inflammatory mediators, PTX3 is synthesized at the inflammatory site by monocytes and endothelial cells in response to inflammatory cytokines. 16 In endothelial cells, PTX3 upregulates tissue factor expression, possibly acting as an endothelial regulator during thrombogenesis and ischemic vascular disease. 17 Also, PTX3 is upregulated during vasculitis, 18 and increased plasma level of PTX3 predicts 3-month survival in patients with acute myocardial infarction. 19, 20 Recent observations have shown that PTX3 is present in atherosclerotic plaques 21 and is expressed by SMCs isolated from human arterial specimens. 22 Moreover, PTX3 binds FGF2 and inhibits its angiogenic activity on endothelial cells. 23 On this basis, we investigated the capacity of PTX3 to affect FGF2-dependent SMC activation in vitro and the impact of recombinant adeno-associated virus (rAAV)-PTX3 gene transfer on neointimal hyperplasia after arterial injury in vivo.
Methods

Chemicals
Human recombinant FGF2 and PTX3 were produced as described. 24, 25 SAP, epidermal growth factor (EGF), and insulin were from Sigma. Neutralizing anti-FGF2 antibodies were from UBI. The recombinant soluble extracellular domain of FGFR-1 (xcFGFR-1) was provided by A. Isacchi (Pharmacia-Upjohn, Nerviano, Italy).
Cell Cultures and rAAV Transduction
Human coronary artery SMCs (HCASMCs) were grown in complete smooth muscle cell growth medium-2 (PBI International) containing 5% fetal calf serum (FCS). pAAV-PTX3 was constructed by cloning the human PTX3 cDNA in pTR-UF5 plasmid (provided by N. Muzyczka, University of Florida, Miami, Fla) to replace the GFP and neomycin-resistance genes. pAAV-LacZ was obtained by inserting the LacZ gene from plasmid pCH110 (Amersham) in the pTR-UF5 backbone. 26 The cloning and propagation of AAV plasmids were carried out in the JC 8111 Escherichia coli strain. Infectious AAV2 vector particles were generated and titered as described. 26 HCASMCs were transduced with AAV-PTX3 or AAVLacZ, and PTX3 and FGF2 protein levels were evaluated in the cell extracts and conditioned media by ELISA (see supplemental Methods, available online at http://atvb.ahajournals.org).
Cell Proliferation and Caspase-3 Activation Assays
Parental or AAV-infected HCASMCs were seeded at 5000 cells/cm 2 in complete smooth muscle cell growth medium-2. After overnight incubation, fresh basal medium containing 0.5% FCS was added and cells were incubated at 37°C in the presence of selected molecules. At selected periods of time, cells were trypsinized and counted in a Burker chamber. The experiments were repeated 3 to 6 times in duplicate. Parallel cell cultures were acetone-fixed and incubated overnight at 4°C with anti-cleaved caspase-3 antibody (Cell Signaling Technology) and then with goat anti-rabbit immunoglobulin G-fluorescein isothiocyanate antibody for 1 hour. Nuclei were stained with 4Ј-6-diamidino-2-phenylindole (DAPI). Next, the percentage of cleaved caspase-3 positive cells was assessed under a fluorescence microscope in 10 random ϫ400 fields per sample.
For 3 H-thymidine incorporation, HCASMCs in basal medium containing 0.5% FCS were added with FGF2 (1.7 nmol/L) in the absence or presence of 220 nmol/L of PTX3 or SAP. After 14 hours, cells were incubated for 10 hours with 3 H-thymidine (2 Ci/mL). Radioactivity incorporated in trichloroacetic acid-insoluble material was determined by scintillation counting and data were expressed as cpm/g of DNA. The experiments were repeated twice in triplicate. Cell viability evaluated at the end of incubation by Trypan blue exclusion was higher than 98% under all experimental conditions.
Chemotaxis Assay
HCASMCs (1x10 6 cells/mL) were seeded in serum-free medium in the upper compartment of a Boyden chamber containing a gelatincoated 5 m PVP free polycarbonate filter (Costar). FGF2s with or without PTX3 or SAP were placed in the lower compartment. After 4 hours at 37°C, cells that migrated to the lower side of the filter were stained with Diff-Quik (Dade-Behring) and 5 random fields were counted for each experimental condition. The experiments were repeated 3 times in triplicate.
Confluent HCASMCs were incubated at 4°C in serum-free medium containing 
Reverse Transcription-Polymerase Chain Reaction Assay
Total RNA was isolated by the TRIzol method from HCASMCs (3ϫ10 4 cells/well in 24-well plates). Total RNA (2 g) was retrotranscribed with Ready-To-Go You-Prime First Strand Beads (Amersham). Then, 1/10 th of the reaction was amplified in a final volume of 25 L using the primers for human PTX3, FGF2, or FGFR-1 (see supplemental Methods). After polymerase chain reaction, 5-L aliquots were separated on a 1.5% agarose gel and visualized by ethidium bromide staining.
Balloon Injury and rAAV Vector Application
A 2F Fogarty catheter was introduced into the common carotid artery of anesthetized male Wistar rats (Harlan, Italy), inflated to 1.5 to 2.0 atmospheres, and a 10-mm injury was induced (see supplemental Methods). After balloon removal, 100-L aliquots of phosphatebuffered saline containing no viral particles (nϭ6), AAV-LacZ (1ϫ10 11 particles, nϭ11), or AAV-PTX3 (1ϫ10 11 particles, nϭ12) were injected through a cannula and allowed to incubate in the injured segment for 40 minutes. The external carotid was then tied and the blood flow was restored. Animals were euthanized after 2 and 4 weeks. Media and neointima areas of injured arteries were quantified and intima-to-media ratios were calculated. PTX3 immunostaining of paraffin-embedded carotid sections was performed 4 weeks after injury using a rabbit polyclonal anti-PTX3 antibody (see supplemental Methods).
Statistical Analysis
Results are expressed as meanϮSEM. Student t test was used for statistical analysis and PϽ0.05 was considered significant.
Results
PTX3 Inhibits FGF2-Induced Proliferation and Chemotaxis in SMCs
SMCs produce FGF2 that, in turn, stimulates their proliferation and migration 3, 4 by interacting with FGFRs. 28 Accordingly, HCASMCs express FGF2 and FGFR-1 transcripts ( Figure 1A, inset) , and anti-FGF2 antibodies (60 nmol/L) inhibit the proliferation of HCASMCs when grown in 0.5% FCS ( Figure 1A ). These data demonstrate the existence of a FGF2-dependent autocrine loop of stimulation in HCASMCs. Under the same experimental conditions, addition of 220 nmol/L of PTX3 to HCASMCs caused a similar inhibitory effect ( Figure 1A) . SAP, which shares a high homology with the PTX3 C-terminus, 29 was ineffective (data not shown).
HCASMCs respond to exogenously added FGF2 with an increase in proliferation rate and DNA synthesis that were suppressed by anti-FGF2 antibodies and PTX3 but not SAP ( Figure 1B and 1C) . PTX3 did not affect the mitogenic activity of insulin, EGF, or serum, confirming the specificity of its FGF2-antagonist activity ( Figure 1D ). FGF2 also exerted a chemotactic activity on HCASMCs (Figure 2A ) which was inhibited by PTX3 but not by SAP ( Figure 2B ).
These data suggest that PTX3 inhibits FGF2-driven stimulation by preventing FGF2 interaction with HCASMCs. Indeed, PTX3 inhibits the binding of 125 I-FGF2 to FGFRs expressed on HCASMCs at doses similar to those required to inhibit the mitogenic and chemotactic activity of FGF2 ( Figure 3A) . To confirm that the interactions of FGF2 with PTX3 or FGFRs are mutually exclusive, plastic-immobilized PTX3 was incubated with 125 I-FGF2 in the presence of xcFGFR-1. As anticipated, xcFGFR-1 prevented the binding of 125 I-FGF2 to immobilized PTX3 ( Figure 3B ).
AAV-PTX3 Transduction Inhibits FGF2-Induced SMC Proliferation and Survival
PTX3 is expressed by vascular SMCs under defined conditions. 21, 22 To assess the effect of endogenous PTX3 on SMC behavior, HCASMCs were infected with an rAAV harboring the human PTX3 cDNA, generating AAV-PTX3 HCASMCs. Preliminary experiments performed with cells transduced with LacZ-AAV (AAV-LacZ HCASMCs) showed that the infection efficiency was higher than 70% (data not shown). AAV-PTX3 infection resulted in the upregulation of PTX3 mRNA in AAV-PTX3 HCASMCs when compared with AAV-LacZ HCASMCs ( Figure 4A, inset) . This was paralleled by an increase of PTX3 protein produced and released by AAV-PTX3-infected cells (PTX3 levels in the conditioned medium of AAV-PTX3 and AAV-LacZ HCASMCs were equal to 100 pmol/L and 8 pmol/L, respectively). AAV infection and consequent PTX3 upregulation did not affect FGF2 expression. Indeed, AAV-PTX3 and AAV-LacZ HCASMCs showed similar levels of cell-associated (4.4 Figure  4A , open symbols). Also, AAV-PTX3 HCASMCs were unable to respond to exogenously added recombinant FGF2. The inhibitory effect was specific because the growth factor maintained its mitogenic activity in control AAV-LacZ HCASMCs ( Figure 4A ).
FGF2 represents an important SMC survival factor. 5 atvb.ahajournals.org). Accordingly, cell number was reduced overtime in PTX3-overexpressing HCASMCs ( Figure 4A) . Similarly, PTX3 protein treatment, like anti-FGF2 antibodies, caused caspase-3 activation in AAV-LacZ HCASMCs (Figure II , available online at http://atvb.ahajournals.org).
Efficacy of AAV-PTX3 in the Reduction of Intimal Hyperplasia
To explore the effects of PTX3 expression in vivo, we evaluated its ability to prevent intimal hyperplasia after arterial injury. Rat carotid arteries infected with AAV-LacZ immediately after balloon injury express ␤-galactosidase with a peak 2 weeks after infection that persists over the following weeks. The marker gene is expressed throughout the vessel wall, maximally in the neointima ( Figure 5D ), including infiltrating SMCs. 30 Therefore, the rat carotid artery of 12 rats was exposed to AAV-PTX3 for 40 minutes immediately after balloon injury. A matched group of control animals received either AAV-LacZ or phosphate-buffered saline. Immunostaining of carotid sections demonstrates that PTX3 is expressed in the intima and media of AAV-PTX3-treated animals both at 2 weeks (data not shown) and 4 weeks after infection when compared with control animals ( Figure 5C ). At these time points, the stenotic response was quantified by measuring the intima and media areas. The thickness of the media of the injured rat carotids was similar in control and AAV-PTX3-treated groups (0.09Ϯ0.01 versus 0.11Ϯ0.01 mm 2 at 2 weeks; 0.10Ϯ0.01 versus 0.12Ϯ0.01 mm 2 at 4 weeks), whereas the neointimal area of the treated group was significantly reduced both at 2 and 4 weeks (0.13Ϯ0.01 versus 0.08Ϯ0.02 mm 2 at 2 weeks, PϽ0.05; 0.18Ϯ0.01 versus 0.15Ϯ0.03 mm 2 at 4 weeks, PϽ0.05) ( Figure 5A and 5B). Accordingly, the intima-to-media ratio, a more sensitive parameter for assessing relative changes in intima and media thickness, was significantly reduced in the AAV-PTX3-treated group compared with controls (55% and 44% inhibition at 2 and 4 weeks, respectively) ( Figure 5E and 5F).
Discussion
The FGF/FGFR system plays a key role in SMC proliferation, migration, and survival in vitro [3] [4] [5] [6] and neointimal thickening after arterial injury. 8, 9 Accordingly, in vivo abrogation of FGF2 activity or FGFR signaling inhibits SMC proliferation after intimal injury. 9, 10, 28 Here we demonstrate that PTX3 exerts a potent FGF2 antagonist activity by suppressing cell proliferation, survival, and migration in HCASMCs and by inhibiting intimal thickening after carotid injury.
HCASMCs express both FGF2 and FGFR-1 transcripts. Anti-FGF2 antibodies suppress the proliferation of HCASMCs maintained under low serum concentrations, demonstrating the existence of an autocrine FGF2 signaling in these cells, as already shown for SMCs of different origin. 5 Exogenously added PTX3 and endogenously overexpressed PTX3 both inhibit this autocrine loop of stimulation. Also, PTX3 fully abolishes the activity of exogenous recombinant FGF2 protein. The short pentraxin SAP, however, does not affect FGF2-dependent cell proliferation and chemotaxis, and PTX3 does not inhibit HCASMC proliferation triggered by insulin, EGF, and serum, underlining the specificity of the FGF2-antagonist effect exerted by PTX3.
The antagonist activity of PTX3 depends on its capacity to bind FGF2 with high affinity, 23 thus acting as a "FGF2 decoy" that sequesters the growth factor in an inactive form. Accordingly, PTX3 prevents the binding of 125 I-FGF2 to FGFRs expressed on HCASMCs. Also, the interactions of FGF2 with PTX3 or soluble xc-FGFR-1 are mutually exclusive. Thus, PTX3 affects the activity of both endogenous and exogenous FGF2 by binding the growth factor and preventing FGFR occupancy in SMCs.
SMCs are permissive to rAAV transduction. 31 Accordingly, we successfully infected HCASMCs with an AAV-PTX3 vector. This resulted in high levels of expression and secretion of PTX3, with the consequent inhibition of the activity exerted in vitro by endogenous and exogenous FGF2. Noticeably, PTX3 produced endogenously after rAAV transduction exerts a more potent FGF2-antagonist activity when compared with PTX3 administered as a single bolus of purified protein (the FGF2-antagonist activity being observed at 100 pmol/L versus 220 nmol/L of PTX3, respectively). This indicates that the continuous production of PTX3 and its release in the microenvironment surrounding the FGF2-target cell, an experimental condition that mimics more closely the in vivo situation, results in an increased ability to interact with the growth factor and to antagonize its activity, further supporting the efficacy of the rAAV gene transfer approach.
In injured rat carotid arteries transduced in vivo with AAV-LacZ, expression of ␤-galactosidase peaks Ϸ2 weeks after infection and persists for several weeks. The marker gene is expressed throughout the vessel wall, maximally in the neointima, with an overall efficiency of transduction equal to approximately 10% of the entire vascular wall ( Figure 5 ). 30 Consistently, in vivo AAV-PTX3 transduction results in PTX3 protein expression in the vessel wall. This was paralleled by a significant decrease in the intima-tomedia ratio at 2 and 4 weeks after injury. FGF2 is produced by SMCs and other cell types in the restenotic area, including endothelial cells, macrophages, and T-cells. 12 Thus, FGF2 may exert autocrine and/or paracrine functions on FGFRexpressing SMCs of the injured vessel. 5, 32 The bulk of our observations strongly suggests that the inhibition of neointimal thickening exerted by rAAV-delivered PTX3 is attributable to its FGF antagonist activity, in keeping with previous studies about the capacity of FGF2 antisense or dominant negative FGFR gene transfer to prevent restenosis. 9, 10 PTX3 is produced at the inflammatory site in response to cytokines and bacterial components. 29, 33, 34 Several cellular components of the blood vessel wall express PTX3, including endothelial cells, 29 macrophages, 34 dendritic cells, 35 adipocytes, 36 fibroblasts 33 and myoblasts. 37 Also, limited levels of PTX3 mRNA and protein are detected in HCASMCs in vitro (present work). Interestingly, PTX3 expression is upregulated by modified atherogenic lipoproteins in SMCs isolated from human arterial specimens. 22 Our observations suggest that PTX3 may exert a modulatory function on SMCs after blood vessel injury by limiting the activity of FGF2. However, this does not seem to be sufficient to prevent the pro-stenotic action of the growth factor, and higher levels of PTX3 expression, like those achieved after rAAV gene transfer, are required to limit neointimal thickness.
Twenty-three members of the FGF family exist that interact with the products of 4 FGFR genes, underlying the complexity of the FGF/FGFR system. 1 Here we have shown that PTX3 affects FGF2/FGFR-1 interaction in HCASMCs. Also, PTX3 can bind FGF8 but not FGF1 or FGF4. 23 Recently, FGF9/FGFR-2 interaction has been implicated in the proliferation of neointimal SMCs after arterial injury. 8 Further studies are required to assess the capacity of PTX3 to affect the activity exerted by different members of the FGF family on SMCs.
